FIGURE 2.
Kaplan–Meier estimates of progression‐free survival in Japanese patients with gastric cancer treated with (A) first‐line pembrolizumab with S‐1 + oxaliplatin (cohort 1) or (B) first‐line pembrolizumab with S‐1 + cisplatin (cohort 2), assessed by central review